Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1997018818) ANTINEOPLASTIC METHODS AND COMPOSITIONS EMPLOYING (+)-FOTEMUSTINE
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1997/018818 International Application No.: PCT/US1996/018488
Publication Date: 29.05.1997 International Filing Date: 19.11.1996
Chapter 2 Demand Filed: 18.06.1997
IPC:
A61K 31/66 (2006.01) ,A61K 31/6615 (2006.01) ,A61P 35/00 (2006.01) ,A61P 35/04 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
66
Phosphorus compounds
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
66
Phosphorus compounds
661
Phosphorus acids or esters thereof not having P-C bonds, e.g. fosfosal, dichlorvos, malathion
6615
Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
04
specific for metastasis
Applicants:
SEPRACOR, INC. [US/US]; 111 Locke Drive Marlborough, MA 01752, US (AllExceptUS)
GRAY, Nancy, M. [US/US]; US (UsOnly)
Inventors:
GRAY, Nancy, M.; US
Agent:
CLEMENT, Candice, J. ; Heslin & Rothenberg, P.C. 5 Columbia Circle Albany, NY 12203, US
Priority Data:
60/007,35820.11.1995US
Title (EN) ANTINEOPLASTIC METHODS AND COMPOSITIONS EMPLOYING (+)-FOTEMUSTINE
(FR) PROCEDES ANTINEOPLASIQUES ET COMPOSITIONS A BASE DE (+)- FOTEMUSTINE
Abstract:
(EN) Methods and compositions are disclosed utilizing optically pure (+)-fotemustine for the treatment of various malignancies, while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of fotemustine.
(FR) L'invention a pour objet des procédés et des compositions à base de (+)- fotémustine, optiquement pure, permettant de traiter diverses malignités, tout en réduisant sensiblement la possibilité d'apparition des effets secondaires défavorables associés à l'administration d'un mélange racémique de la fotémustine.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN
African Regional Intellectual Property Organization (ARIPO) (KE, LS, MW, SD, SZ, UG)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0868189JP2000500495CN1207040CA2237909AU1996077378AU2000072294